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Abstract
Background: Limited information exists regarding the association between serum uric acid (SUA) and psychiatric disorders.
We explored the relationship between SUA and subtypes of major depressive disorder (MDD) and specific anxiety disorders.
Additionally, we examined the association of SLC2A9 rs6855911 variant with anxiety disorders.
Methods: We conducted a cross-sectional analysis on 3,716 individuals aged 35–66 years previously selected for the
population-based CoLaus survey and who agreed to undergo further psychiatric evaluation. SUA was measured using
uricase-PAP method. The French translation of the semi-structured Diagnostic Interview for Genetic Studies was used to
establish lifetime and current diagnoses of depression and anxiety disorders according to the DSM-IV criteria.
Results: Men reported significantly higher levels of SUA compared to women (357674 mmol/L vs. 263664 mmol/L). The
prevalence of lifetime and current MDD was 44% and 18% respectively while the corresponding estimates for any anxiety
disorders were 18% and 10% respectively. A quadratic hockey-stick shaped curve explained the relationship between SUA
and social phobia better than a linear trend. However, with regards to the other specific anxiety disorders and other
subtypes of MDD, there was no consistent pattern of association. Further analyses using SLC2A9 rs6855911 variant, known to
be strongly associated with SUA, supported the quadratic relationship observed between SUA phenotype and social
phobia.
Conclusions: A quadratic relationship between SUA and social phobia was observed consistent with a protective effect of
moderately elevated SUA on social phobia, which disappears at higher concentrations. Further studies are needed to
confirm our observations.
Citation: Lyngdoh T, Bochud M, Glaus J, Castelao E, Waeber G, et al. (2013) Associations of Serum Uric Acid and SLC2A9 Variant with Depressive and Anxiety
Disorders: A Population-Based Study. PLoS ONE 8(10): e76336. doi:10.1371/journal.pone.0076336
Editor: Chunyu Liu, University of Illinois at Chicago, United States of America
Received April 5, 2013; Accepted August 22, 2013; Published October 29, 2013
Copyright:  2013 Lyngdoh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The PsyCoLaus study was supported by grants from the Swiss National Science Foundation (#3200B0-105993) and from GlaxoSmithKline (Psychiatry
Center of Excellence for Drug Discovery and Genetics Division, Drug Discovery - Verona, R&D). Profs PV and GW received an unrestricted grant from
GlaxoSmithKline to build the CoLaus study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors would like to disclose again that Profs PV and GW received an unrestricted grant from GlaxoSmithKline to build the CoLaus
study. However, this does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. The other authors report no conflict of
interest.
* E-mail: Murielle.Bochud@chuv.ch
Introduction
Uric acid, a key end-product of purine metabolism, has a
controversial role in human physiology acting potentially both as a
pro-oxidant and selective antioxidant depending on its environ-
mental milieu. It functions as an antioxidant primarily in
extracellular compartment and as a pro-oxidant within the cells.
While its role as a pro-oxidant in cardio-metabolic and cardio-
vascular diseases is well established, it has been observed that
subjects with elevated serum uric acid (SUA) have lower
prevalence of neurodegenerative diseases like multiple sclerosis,
Parkinson’s disease and Alzheimer’s disease [1,2,3,4]. Such a
neuroprotective effect of SUA could be attributed to its
antioxidant properties. Uric acid is capable of scavenging
superoxide and hydroxyl radicals [5,6] and accounts for over
60% of total antioxidant capacity in the human blood [5].
Though studies examining the role of SUA in affective disorders
like major depressive disorder (MDD) and anxiety disorders are
scant, the available evidence suggests a protective role of SUA in
both depression [7,8,9] and anxiety [10]. The exact pathophys-
iologic mechanism linking SUA to these disease states is still
unclear. Oxidative stress-related pathways have been implicated in
depression and anxiety based mostly on experimental evidence
[11,12,13,14] and also several studies in humans [15,16]. Hence,
one possible mechanism by which SUA exerts its protective effect
could be via a decrease in oxidative stress.
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The few studies that have looked at the relation between SUA
and MDD and anxiety disorders [7,8,9,10] have methodological
limitations which include small sample sizes and/or samples not
representative of the general population. Hence, the current
analysis explored the relationship between SUA and the lifetime
and current occurrence of the commonest psychiatric disorders
including the subtypes of MDD and specific anxiety disorders in
individuals from a large population-based study. In addition, we
examined the associations between a key variant of the SLC2A9
gene which has been shown to have a strong association with SUA
in genome-wide association studies [17,18] and anxiety disorders.
Methods
Study population
Current analyses are performed within the PsyCoLaus study
which is the psychiatric arm of the CoLaus study, a population-
based study that assessed cardiovascular disease (CVD) risk factors
and genetic variants associated with these conditions in Lausanne,
Switzerland. Details of the CoLaus have been previously described
[19]. Briefly, the random sampling procedure was based on a
complete list of the Lausanne inhabitants aged 35–75 years in
2003, provided by the population register of the city. Sixty-seven
percent of the CoLaus participants in the age range between 35
and 66 years (n = 5,535) accepted the psychiatric evaluation
between 2004 and 2008, which resulted in a sample of 3,716
individuals who underwent both the medical and psychiatric exam
[20]. Ninety-two percent of them were Caucasians. The gender
distribution of the PsyCoLaus sample (47% males) did not differ
significantly from that of the general population in the same age
range. Although the youngest 5-year band of the cohort was
underrepresented and the oldest 5-year band overrepresented,
participants of PsyCoLaus (mean age 50.968.8 years) and
individuals who refused to participate revealed comparable scores
on the General Health Questionnaire (GHQ-12 [21]; French
translation [22]), a self-rating instrument completed at the somatic
exam. Both CoLaus and PsyCoLaus were approved by the Ethics
Committee of the University of Lausanne. A written informed
consent was obtained only from individuals without any apparent
disability or handicap that might suggest the participant’s
incapability to participate in the study.
Study procedure and measurements
Evaluations within the CoLaus study. Participants of the
CoLaus study were seen in the outpatient clinic of the Centre
Hospitalier Universitaire Vaudois (CHUV) in the morning after
an overnight fast. They were asked to continue taking their
medications as usual. The examination included a detailed health
questionnaire, physical examination with anthropometric mea-
sures by trained and certified field workers and laboratory testing.
Information on drugs that influence uric acid was assessed by
recording all the prescribed drugs taken by the participants and
was considered as present if participants were using any drugs
including acetylsalicylic acid, diuretics, angiotensin converting
enzymes inhibitors, angiotensin receptor blockers and other drugs
known to induce hyperuricemia and hypouricemics (e.g., allopu-
rinol, probenecid etc.). Blood pressure was measured in triplicate
on the left arm and blood pressure values are the mean between
the last two readings. Most clinical assays were performed by the
CHUV Clinical Laboratory on fresh fasting blood samples.
Glucose was measured by glucose dehydrogenase (2.1% - 1.0%
maximum inter and intra-batch coefficients of variation); serum
and urinary creatinine by Jaffe kinetic compensated method (2.9%
- 0.7%) and uric acid by uricase-PAP (1.0% - 0.5%). Glomerular
filtration rate (GFR) was estimated using the abbreviated
Modification of the Diet in Renal Disease (MDRD) formula:
1866(serum creatinine [mmol/L]/88.4) (21.154)6age
(20.203)6F, where F= 1 for men and F= 0.742 for women [23].
Hypertension was defined as mean systolic blood pressure of
$140 mmHg or mean diastolic blood pressure of $90 mmHg
and/or presence of anti-hypertensive medication. A diagnosis of
diabetes was made if fasting plasma glucose was greater than or
equal to 7.0 mmol/l or presence of oral hypoglycaemic or insulin
treatment.
Evaluations within PsyColaus study. Diagnostic informa-
tion was collected using the semi-structured Diagnostic Interview
for Genetic Studies (DIGS) [24]. The DIGS was developed by the
NIMH Molecular Genetics Initiative to obtain a more precise
assessment of phenotypes through wide spectrum of DSM-IV Axis
I criteria. The French translation of the DIGS [25] used in this
study was jointly developed by the Department of Psychiatry of
Lausanne and the INSERM in Paris and had several modifica-
tions. Additional questions were added to the depression section in
order to elicit criteria for atypical depression features (leaden
paralysis, long-standing patterns of interpersonal rejection sensi-
tivity, mood reactivity). Similarly, a section on generalized anxiety
disorder (GAD) was added using questions from the Schedule for
Affective Disorders and Schizophrenia-Lifetime (SADS-LA) ver-
sion and the brief phobia chapter of the DIGS was replaced by the
corresponding more extensive chapters from the SADS-LA [26].
The French version of the DIGS had excellent inter-rater
reliability for kappa and Yule’s Y coefficient for major mood
disorders [27] but 6-week test-retest reliability was slightly lower
[27]. Similarly, the French translation of the SADS-LA revealed
satisfactory test-retest reliability for anxiety disorders [28]. In our
own reliability study we found excellent or perfect inter-rater
reliability for all specific anxiety disorders, whereas the 6-week test-
retest reliability estimates were in the fair or good range [29].
Lifetime and current (at the time of interview) diagnoses of
depression and anxiety disorders were assigned according to
DSM-IV criteria. The specifier for atypical depression features
according to DSM-IV requires mood reactivity (the capacity to be
cheered up when presented with positive events) and at least two of
the following four symptoms: 1) increased appetite or significant
weight gain, 2) hypersomnia, 3) leaden paralysis (i.e., heavy, leaden
feelings in arms or legs), and 4) a long-standing pattern of
interpersonal rejection sensitivity. According to Angst et al. [30],
we used these criteria in a non-hierarchical way (depressive
episode meeting at least 3 out of the 5 DSM-IV criteria of the
atypical depression features specifier). For melancholic depression
features, we applied the DSM-IV specifier which requires either a
loss of energy or a lack of mood reactivity and 3 out of the
following 5 symptoms: 1) depression regularly worse in the
morning, 2) early morning awakening, 3) psychomotor retardation
or agitation, 4) decreased appetite (we did not consider weight loss
as a criterion) and 5) excessive guilt. We could not take into
account the 6th DSM-IV criterion ‘‘distinct quality of depressed
mood’’ because it was not assessed in the DIGS. Following Angst
et al. [30], MDD was subtyped according to the history of atypical
or melancholic features into four subtypes 1) MDD with atypical
features only, 2) MDD with melancholic features only, 3)
combined MDD with atypical and melancholic features simulta-
neously or during distinct episodes and 4) unspecified MDD with
neither atypical, nor melancholic features. All interviews were
conducted by psychologists and psychiatrists trained over a two-
month period. Their training included rating tapes and supervised
co-ratings. Each interview and diagnostic assignment was reviewed
by an experienced senior psychologist.
Serum Uric Acid, Depressive and Anxiety Disorders
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e76336
Socio-economic status was assessed using the Hollingshead scale
[31]. Smoking was defined as current or past history of regular
daily consumption of at least 10 cigarettes. Alcohol consumption
was defined as glasses per typical week of consumption.
Genotyping. Nuclear DNA was extracted from whole blood
for whole genome scan analysis. Genotyping was performed using
Affymetrix 500K SNP chip, as recommended by the manufacturer
(Affymetrix, Inc., Santa Clara, California, USA) on all participants
of the CoLaus study. Persons with less than 95% genotyping
efficiency overall (or,90% efficiency on either array; n= 399) and
persons with possible gender inconsistencies (n = 5) were removed.
Monomorphic single nucleotide polymorphisms (SNPs), SNPs
with less than 70% genotyping efficiency, SNPs with minor allele
frequency less than 1%, and/or not in the Hardy-Weinberg
proportions were excluded. The SNP rs6855911 in the SLC2A9
gene was considered for the present analysis.
Statistical analysis
All tests were performed using Stata 11 (StataCorp, College
Station, TX, USA). Continuous variables were summarized as
mean (standard deviation) or median (interquartile range) while
categorical variables as number of subjects and percentages. We
used t test (or Wilcoxon rank sum test) and x2 test to compare the
distribution of covariates according to sex. We described the
distribution of MDD and anxiety disorders across sex-specific SUA
quintiles and across genotypes of rs6855911 within the SLC2A9
gene and assessed for trends across these groups by using a non-
parametric test which is an extension of the Wilcoxon rank-sum
test [32]. These quintiles were generated separately in men and
women, which leads to an equal proportion of men and women
across quintiles.
We constructed multiple logistic regression models to examine
the associations of SUA as independent variable of interest with
MDD, MDD subtypes or specific anxiety disorders as dependent
variable, one at a time. The predictor variable SUA was modeled
as a continuous variable. Co-variates that were known to
potentially influence the associations such as age, sex, socio-
economic status, smoking, alcohol consumption, diabetes, hyper-
tension, GFR and drugs that influence SUA were included in the
models. Because depression and anxiety tend to co-exists [33,34],
we additionally adjusted for any anxiety disorder (in the
association between SUA and depression) and MDD (in the
association between SUA and anxiety). Furthermore, we included
a quadratic term for SUA (i.e. SUA squared) in the models to
account for non-linear relationship and used a likelihood ratio test
(LRT) to compare model assuming a linear trend for SUA with
another estimating quadratic fit; we maintained a quadratic model
if the quadratic term was significant and P-value from the LRT
was ,0.05. Stratified analyses by sex were also conducted. We
presented the quadratic relationship between SUA and social
phobia graphically by plotting the fitted predicted probabilities
after adjusting for the co-variates across SUA levels and by
presenting the distribution of lifetime social phobia in men and
women across genotypes of SLC2A9 rs6855911 variant.
To test the potential modification of this association by sex, we
included a multiplicative interaction parameter between sex and
SUA into the logistic models. For models which included a
quadratic term for SUA, interaction by sex was determined by
LRT comparing a model with the multiplicative interaction
parameters (SUA*sex and SUA squared*sex) to one without. We
also performed logistic regression analyses where we further
modeled SLC2A9 rs6855911 as a score (where 0 =homozygote for
non-risk allele, 1 = heterozygote and 2= homozygote for risk allele)
with anxiety disorders. The results from the genetic analyses serve
to validate findings from logistic models using phenotypic SUA.
We also tested the sex-by-genotype interaction for its effect on
anxiety disorders in models including both men and women.
Results
Table 1 characterizes the demographic and clinical character-
istics of the participants according to sex. SUA was significantly
higher in men (357674 mmol/L) than in women (263664 mmol/
L). Men had significantly higher prevalence of reported alcohol
consumption and smoking compared to women. The overall
prevalence estimates of diabetes and hypertension in the study
population were 5% and 28% respectively, with significantly
higher prevalence in men. The frequency of mental disorders in
the overall population was high, with prevalence of lifetime and
current MDD being 44% and 18% respectively. The correspond-
ing prevalence estimates for any anxiety disorders were 18% and
10% respectively. Women consistently showed significantly higher
lifetime as well as current prevalence of all subtypes of MDD and
specific anxiety disorders (p,0.001 in almost all cases).
Table 2 describes the distribution of the lifetime and current
prevalences of MDD and anxiety disorders across sex-specific
quintiles of SUA in the overall sample. A significant negative linear
trend was observed for anxiety disorder, in general, and for social
phobia, in particular, suggesting lower prevalence of lifetime and
current social phobia at higher levels of SUA. However, this
decreasing trend in prevalence of social phobia was only up to a
certain level of SUA after which an increase in prevalence was
detected. Testing for comparison of fit of linear versus quadratic
model indicated that a quadratic curve might explain the
relationship better than a linear trend. In stratified analysis by
sex (Tables S1 and S2), a hockey-stick shaped relationship (i.e.
lowest prevalence in the fourth quartile) between SUA and lifetime
and current social phobia was observed in women, although the
quadratic test for trend was not statistically significant (P-value for
quadratic trend= 0.153 and 0.087 respectively). A hockey-stick
shaped relationship also tended to be present in men (P-value for
quadratic trend= 0.095 and 0.210 respectively), although less clear
than in women, possibly owing to the small number of cases of
social phobia in each SUA quintile. Figure S1 depicts the
quadratic trend between SUA and social phobia based on adjusted
predicted probabilities of social phobia across SUA levels from a
multiple logistic regression model.
Table 3 shows the associations of SUA with MDD and anxiety
disorders in the overall sample either from models with or without
the quadratic term for SUA depending on whether quadratic or
linear model was a better fit. Both crude and adjusted analyses
showed significant inverse associations of SUA with lifetime and
current social phobia. With regards to the other specific anxiety
disorders and subtypes of MDD, we found no consistent pattern of
association. Although we did not observe any significant interac-
tion between sex and SUA for any of the lifetime and current
psychiatric disorders, separate analysis in males and females are
presented in Tables S3 and S4.
The next set of analyses explored the association of uric acid
with anxiety disorders using SLC2A9 rs6588911 variant instead of
phenotypic values for SUA. Logistic regression models (Table 4)
revealed significant interactions between sex and SUA as
explained by the SLC2A9 rs6855911 variant regarding any anxiety
disorder (P-value for the interaction= 0.026 and 0.014 for lifetime
and current disorders, respectively) and social phobia (P-value for
the interaction= 0.033 and 0.015 for lifetime and current disorder,
respectively). Therefore, we present all analyses regarding the
association of the SUA-related rs6855911 variant with anxiety
Serum Uric Acid, Depressive and Anxiety Disorders
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disorders separately in men and women. While a significant
positive association of the allele associated with higher SUA levels
(rs6855911 A allele) with lifetime and current social phobia was
observed in men, a negative association, though not significant,
was noticed in women. Considering that women have lower SUA
levels than men at each rs6855911 genotype (see below), the
observed effect modification by sex is consistent with the quadratic
association of SUA with social phobia in non-genetic analyses.
We present the distribution of SUA and anxiety disorders across
SUA-related rs6855911 variant separately in men and women in
Table 5. In women, a negative (although not significant) linear
trend of social phobia was noted across genotypes associated with
increasing levels of SUA similar to that observed in Table S2 using
phenotypic SUA levels. On the other hand, a significant positive
linear trend was seen in men, which was in contrast to that
observed in women and also to the analysis that used SUA
phenotype (in Table S1). Further, we graphically displayed in
Figure S2 the distribution of SUA and prevalence of social
phobia across genotypes of the variant SLC2A9 rs6855911
separately in men and women. Both men and women who carried
the AA genotype had elevated levels of SUA as compared to
carriers of the GG genotype. While in women a lower prevalence
of social phobia was found in carriers of the AA genotype
associated with higher SUA levels, the opposite trend was observed
in men. Further, we observed a P-value of 0.014 for a LRT for a
quadratic trend using the genetic variable coded as 0, 1, 2, 3, 4 and
5 where 0 =GG in females, 1 =AG in females, 2 =AA in females,
3 =GG in males, 4 =AG in males and 5=AA in males (data not
shown). This coding was chosen because it ranks these 6
independent groups of people according to increasing lifelong
SUA levels. Taken together, these results are consistent with a
quadratic relationship between SLC2A9 genotypes (i.e. genetically
Table 1. Characteristics of the PsyCoLaus participants.
Overall (N=3716) Men (N=1748) Women (N=1968)
N
% or mean
(s.d.) N
% or mean
(s.d.) N
% or mean
(s.d.) P
Age (years)* 3716 50.9(8.8) 1748 50.5(8.8) 1968 51.3(8.8) 0.006
Alcohol consumption1 3716 3.0(0.0–8.0) 1748 6.0(2.0–14.0) 1968 2.0(0.0–5.0) ,0.001
Daily smoking (.10 cigarettes) 1655 44.5 869 49.7 786 39.9 ,0.001
Diabetes 194 5.2 139 8.0 55 2.8 ,0.001
Hypertension 1046 28.2 588 33.6 458 23.3 ,0.001
Drugs influencing uric acid levels 471 13.8 247 15.3 224 12.4 0.014
Serum uric acid (mmol/L)* 3710 307.1(83.5) 1744 357.2(73.7) 1966 262.6(64.3) ,0.001
GFR (ml/min/1.73 m2)* 3709 84.4(15.8) 1743 87.2(0.4) 1966 81.9(0.3) ,0.001
Lifetime pyschiatric disorders
MDD 1625 43.7 565 32.3 1060 53.9 ,0.001
Combined MDD 218 5.9 61 3.5 157 8.0 ,0.001
Atypical MDD 236 6.4 70 4.0 166 8.4 ,0.001
Melancholic MDD 449 12.1 151 8.6 298 15.1 ,0.001
Unspecified MDD 722 19.4 283 16.2 439 22.3 ,0.001
Any anxiety disorder 660 17.8 225 12.9 435 22.1 ,0.001
GAD 85 2.3 29 1.7 56 2.9 0.043
Panic disorder 118 3.2 30 1.7 88 4.5 ,0.001
Agoraphobia 139 3.7 32 1.8 107 5.4 ,0.001
Social phobia 444 12.0 162 9.3 282 14.3 ,0.001
Current psychiatric disorders
MDD 660 17.8 236 13.5 424 21.5 ,0.001
Combined MDD 106 2.9 30 1.7 76 3.9 ,0.001
Atypical MDD 98 2.6 31 1.8 67 3.4 0.002
Melancholic MDD 198 5.3 66 3.8 132 6.7 ,0.001
Unspecified MDD 258 6.9 109 6.2 149 7.6 0.110
Any anxiety disorder 370 10.0 118 6.8 252 12.8 ,0.001
GAD 0 0.0 0 0.0 0 0.0 NA
Panic disorder 1 0.0 0 0.0 1 0.1 NA
Agoraphobia 88 2.4 21 1.2 67 3.4 ,0.001
Social phobia 294 7.9 98 5.6 196 10.0 ,0.001
1median (interquartile range);
*mean (standard deviation).
GFR = glomerular filtration rate; MDD=major depressive disorder; and GAD=generalized anxiety disorder.
doi:10.1371/journal.pone.0076336.t001
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determined SUA levels) and social phobia, which was similar to
what we observed in Figure S1.
Discussion
To the best of our knowledge, this is by far the largest
population-based study to assess the relationship of SUA with
depressive and anxiety disorders. We found a significant quadratic
(hockey-stick shaped) association between SUA with both lifetime
and current social phobia suggesting that elevated levels of SUA
are associated with lower frequency of social phobia only up to a
certain concentration after which increasing SUA levels are no
longer protective. It is interesting to note that SUA does not
appear to be protective when in the range of hyperuricemia.
We observed a similar quadratic relationship between SLC2A9
rs6855911 (associated with increasing levels of uric acid) and social
phobia when keeping both men and women in the analysis.
Similar to what was observed for the non-genetic association, the
overall quadratic association of rs6855911 genotypes with social
phobia disappeared when stratifying the analyses by sex. Findings
from genetic associations are generally considered to be free from
the inherent problems of reverse causation and confounding.
Recent genome wide association studies have identified SLC2A9
gene, a putative hexose transporter, to be strongly associated with
SUA [18,35,36]. SLC2A9 gene explains a substantial proportion
(1–6%) of the variance in SUA concentration [37]. Considering
that genes are inherited at the time of conception from parents
through random transmission, genetic associations of single
nucleotide polymorphisms (SNPs) within or around the genes will
be less likely to be influenced by problems of reverse causality or
measurement errors inherent to conventional observational studies
and more likely to produce robust causal inferences. The results of
the genetic associations for social phobia using the SLC2A9
rs6855911 variant serve to validate the findings of the observa-
tional analysis. It confirmed the finding that SUA does not confer
protective effects beyond a certain concentration as evidenced
from the negative association (i.e., those carrying the allele related
to elevated levels of SUA were associated with decreased risk of
social phobia) observed in women and the opposite association in
men. Women have much lower SUA levels than men [38], due to
the uricosuric effects of estrogen [39]. Our findings provide new
insights which need to be replicated in other settings.
Very few studies have explored the association between SUA
and anxiety disorders. The earliest study dating back to 1979 and
carried out on 20 students aged between 18–30 years found levels
of SUA to be significantly decreased during periods of anxiety
[10]. Similar decreases in SUA levels in stressful situations have
been observed. Trevisan et al. observed exposure to a natural
disaster (major earthquake) in 578 healthy factory workers in
Naples to be associated in the short term with a reduction and in
the long-term with an increase in SUA levels [40]. More recently,
a study in Japan found no association between SUA and post-
traumatic stress disorder in 34 victims of the Tokyo Sarin attack.
However, the authors do acknowledge that lack of association
could have been due to the limited sample size and 5-year time
Table 2. Distribution of psychiatric disorders across sex-specific quintiles of SUA.
SUA (mean, mmol/L) Q1 224 Q2 273 Q3 306 Q4 343 Q5 422 P-trend
N(%) N(%) N(%) N(%) N(%) (Test statistic)
Lifetime pyschiatric disorders
MDD 348(47.2) 323(45.4) 296(40.8) 259(40.1) 251(42.5) 0.012(22.51)*
Combined MDD 45(6.1) 44(6.2) 46(6.3) 33(5.1) 35(5.9) 0.624(20.49)
Atypical MDD 46(6.2) 45(6.3) 39(5.4) 44(6.8) 40(6.8) 0.623(0.49)
Melancholic MDD 104(14.1) 94(13.2) 76(10.5) 64(9.9) 70(11.9) 0.038(22.07)
Unspecified MDD 153(20.7) 140(19.7) 135(18.6) 118(18.3) 106(18.0) 0.144(21.46)
Any anxiety disorder 162(22.0) 126(17.9) 130(18.0) 102(15.9) 103(17.6) 0.015(22.43)*
GAD 15(2.0) 16(2.3) 14(1.9) 16(2.5) 17(2.9) 0.316(1.00)
Panic disorder 24(3.3) 17(2.4) 30(4.2) 26(4.0) 14(2.4) 0.965(0.04)
Agoraphobia 26(3.5) 26(3.7) 34(4.7) 29(4.5) 20(3.4) 0.735(0.34)
Social phobia 126(17.1) 84(11.9) 84(11.7) 55(8.6) 70(11.9) ,0.001(23.62)*
Current psychiatric disorders
MDD 163(22.1) 126(17.7) 130(17.9) 117(18.1) 121(20.5) 0.469(20.72)
Combined MDD 24(3.3) 21(3.0) 23(3.2) 14(2.2) 24(4.1) 0.764(0.30)
Atypical MDD 20(2.7) 22(3.1) 16(2.2) 18(2.8) 21(3.6) 0.540(0.61)
Melancholic MDD 55(7.5) 43(6.0) 38(5.2) 34(5.3) 27(4.6) 0.020(22.32)
Unspecified MDD 64(8.7) 40(5.6) 53(7.3) 51(7.9) 49(8.3) 0.700(0.38)
Any anxiety disorder 97(13.1) 71(10.0) 78(10.8) 50(7.7) 54(9.2) 0.005(22.83)*
GAD 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0) NA
Panic disorder 0(0.0) 1(0.1) 0(0.0) 0(0.0) 0(0.0) NA
Agoraphobia 16(2.2) 17(2.4) 23(3.2) 18(2.8) 10(1.7) 0.869(20.17)
Social phobia 85(11.5) 55(7.7) 59(8.1) 34(5.3) 45(7.6) 0.001(23.21)*
MDD= major depressive disorder; GAD=generalized anxiety disorder; and SUA= serum uric acid.
*P-value ,0.05 for quadratic trend tested by a crude logistic model which included a quadratic term (SUA squared) for continuous value of SUA.
doi:10.1371/journal.pone.0076336.t002
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gap between the event and the study [41]. Our finding of an
inverse association between SUA level and social phobia (the most
common anxiety disorders [42]), which is an indicator of
permanent social stress, are consistent with previous studies that
reported decreased SUA levels in periods of stress and anxiety.
Similar findings were also documented from longitudinal studies
on US navy men undergoing training as a part of the Navy
Underwater Demolition Team [43,44,45]. SUA varied signifi-
cantly with elevated levels during periods of rigorous training for
challenging tasks that were eagerly awaited and decreased levels
during periods of unanticipated intense psychological and physical
stress. Moreover, a similar experiment by the same group on three
medical investigators over six-month periods also revealed
increases in SUA levels above baseline in situations prior to a
physical challenge in which the associated stress is eagerly
anticipated as a pleasant challenge [46].
Although three previous studies documented negative associa-
tions between SUA level and depression, we did not find such an
association of SUA with MDD or its subtypes. In the first study of
826 individuals with age ranging from 16–86 years Wen et al
found depressive patients (based on scores from the Hamilton
Depression Scale (HAMD24)) to have significantly lower SUA
levels as compared to patients with other mental disorders and
healthy controls [9]. Similarly, a significant negative correlation
between SUA and Zung Self-Rating Depression Scale scores was
observed in another population-based (the Massa Lombarda
Project) study on 106 subjects with a mean age of about 80 years
[7]. The third study, a randomized controlled trial, among age and
sex-matched 40 MDD based on the Hamilton Rating Scale for
Depression scores and 36 healthy subjects before and after anti-
depressive drug treatment found significantly lower SUA levels in
newly diagnosed MDD subjects compared to healthy subjects with
a reverse trend after 12 weeks of treatment [8]. Differences in the
sampling or the use of different instruments to assess depression
are likely to account for the different results in the present study as
compared to the three previous studies. Indeed, two of the three
previous studies included treated depressive subjects, who were
likely to be more severely affected than the depressive sample of
the present population-based study.
The exact mechanisms of action linking SUA with anxiety
disorders still remains elusive. Oxidative stress has recently gained
attention as one of the suggested mechanisms in the pathophys-
iology of MDD and anxiety disorders. Evidence from experimen-
tal studies clearly supports this hypothesis [11,12,13,14]. These
findings further extend to studies in humans where elevated
oxidative stress levels have been observed in patients with
depression [16,47,48,49] and anxiety [15]. Oxidative stress
characterized by an excess generation of reactive oxygen species
can affect a number of physiological functions including the
central nervous system. The brain has modest antioxidant levels
and is particularly vulnerable to the detrimental effects of oxidative
stress as the neuronal membrane containing a high proportion of
polyunsaturated fatty acids is a key site for oxidative stress [50].
Uric acid, by virtue of its powerful anti-oxidant properties [5], may
provide a defense against the oxidative stress [51]. In addition,
recent observations have also attributed the protective effect of
Table 4. Crude and adjusted logistic regression analysis of SLC2A9 rs6855911 and psychiatric disorders according to sex.
Men Women
OR(95% CI) P-value OR(95% CI) P-value Pinteraction
Lifetime pyschiatric disorders
Any anxiety disorder Unadjusted 1.38(1.05–1.80) 0.019 0.94(0.78–1.14) 0.525
Adjusted 1.40(1.07–1.84) 0.015 0.97(0.80–1.17) 0.728 0.026
GAD Unadjusted 1.22(0.58–2.57) 0.601 0.94(0.58–1.51) 0.797
Adjusted 1.22(0.57–2.62) 0.602 0.94(0.58–1.52) 0.793 0.520
Panic disorder Unadjusted 1.57(0.76–3.26) 0.225 0.80(0.55–1.15) 0.224
Adjusted 1.50(0.72–3.14) 0.277 0.82(0.56–1.19) 0.298 0.128
Agoraphobia Unadjusted 1.50(0.77–2.92) 0.230 1.00(0.71–1.42) 0.979
Adjusted 1.61(0.82–3.18) 0.168 1.03(0.72–1.47) 0.865 0.287
Social phobia Unadjusted 1.43(1.05–1.96) 0.025 0.93(0.75–1.17) 0.559
Adjusted 1.44(1.05–1.99) 0.023 0.96(0.76–1.21) 0.720 0.033
Current psychiatric disorders
Any anxiety disorder Unadjusted 1.42(1.00–2.03) 0.053 0.82(0.65–1.04) 0.097
Adjusted 1.42(0.99–2.03) 0.055 0.84(0.66–1.06) 0.140 0.014
Agoraphobia Unadjusted 1.15(0.54–2.45) 0.713 0.84(0.54–1.29) 0.421
Adjusted 1.19(0.56–2.57) 0.649 0.85(0.55–1.32) 0.477 0.466
Social phobia Unadjusted 1.51(1.02–2.25) 0.042 0.82(0.63–1.06) 0.124
Adjusted 1.50(1.00–2.23) 0.049 0.83(0.64–1.09) 0.184 0.015
GAD=generalized anxiety disorder.
ORs represent the effect of SLC2A9 rs6855911 used as a continuous score of 0, 1 and 2 corresponding to GG, AG and AA genotype respectively with AA being the
genotype associated with elevated levels of serum uric acid.
Adjusted for age, sex, socio-economic status, alcohol consumption, smoking, diabetes, hypertension, GFR (calculated according to Modification in Diet in Renal Disease
equation) and drugs that influence uric acid and additionally for anxiety (in the association between SUA and depression) and depression (in the association between
SUA and anxiety).
Pinteraction = P value for sex-by-genotype interaction for its effect on psychiatric disorders.
doi:10.1371/journal.pone.0076336.t004
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SUA to its ability to decrease blood-brain barrier permeability as
well as a more direct effect on astroglial cells [52,53]. However, the
relation between SUA and anxiety may not be as straightforward
as it appears, which is also reflected in the non-linear relationship
observed in the current study. This is not surprising and probably
relates to the complex and paradoxical role of uric acid in the
‘‘antioxidant – prooxidant urate redox shuttle’’ which states that
‘‘in a prooxidative environmental milieu the original antioxidant
properties of uric acid paradoxically become prooxidant’’ [54].
Furthermore, it is difficult to distinguish whether lowered SUA
levels observed in depressed and anxious subjects is a cause or
consequence of the disease. As Wen and colleagues pointed out, it
is unclear if depressed patients with low SUA levels are more likely
to be challenged with free radical toxicity and inflammation or
rather low SUA is due to the consumption of uric acid by radical
interaction and damaged tissue encountered in anxiety or
depression [9].
The strengths of this study are its population-based design, the
large sample size, the face-to-face structured interview-based
psychiatric diagnoses, the availability of detailed information on a
number of potential confounders known to influence the
association and the accessibility to genetic markers that allowed
for validating the findings from phenotypic analyses. The potential
limitations are: first, the cross-sectional nature of the study with the
establishment of lifetime diagnoses of MDD and anxiety disorders
which did not allow us to infer causality of non-genetic findings.
However, the findings from the genetic analysis using SLC2A9
rs6855911 corroborated the results from the phenotypic analysis
(where SUA was used). Indeed, inferences drawn from genetic
analyses are usually more robust and can be considered as causal.
Second, there was a gap of about one year [median (interquartile
range) being 1.2(1.1–1.3) years] between the evaluation of SUA
and assessments of psychiatric phenotypes. However, evidence
have shown that SUA taken 5 years apart have a high correlation
(r = 0.50) [55] which makes it unlikely that the subjects would have
very different levels of SUA after an interval of one year.
In conclusion, in this population-based sample, we found a
quadratic (hockey-stick shaped) relation between SUA and social
phobia, with both non-genetic and genetic associations, consistent
with a potential protective effect of moderately elevated SUA on
social phobia, which disappears when SUA levels reach the
hyperuricemic zone. Since the use of genetic variants reflecting
lifelong differences in SUA levels is usually robust to confounding
and reverse causality, our results suggest that the observed
association may be causal. However, prospective observational
and experimental studies are needed to confirm our observations.
Supporting Information
Figure S1 A quadratic curve association between serum
uric acid (SUA) and social phobia. The dots and bars
represent the adjusted probabilities along with 95%CI of social
Table 5. Distribution of SUA and psychiatric outcomes across genotypes of SLC2A9 rs6855911 in men and women.
GG AG AA P-trend
MEN (N) 107 544 706
SUA (mean, SD) mmol/L 317.96(76.11) 352.57(69.60) 367.63(74.75) ,0.001
Lifetime pyschiatric disorders (N, %)
Any anxiety disorders 8(7.55) 62(11.44) 104(14.81) 0.014
GAD 1(0.94) 7(1.29) 11(1.57) 0.556
Panic disorder 0(0.00) 9(1.66) 14(1.99) 0.203
Agoraphobia 2(1.89) 7(1.29) 18(2.57) 0.211
Social phobia 6(5.66) 42(7.75) 77(10.98) 0.019
Current psychiatric disorders (N, %)
Any anxiety disorders 5(4.67) 31(5.70) 59(8.36) 0.044
Agoraphobia 2(1.87) 5(0.92) 11(1.56) 0.694
Social phobia 3(2.80) 26(4.78) 49(6.94) 0.034
WOMEN (N) 108 653 780
SUA (mean, SD) mmol/L 220.73(50.36) 251.60(61.36) 278.87(62.69) ,0.001
Lifetime pyschiatric disorders (N, %)
Any anxiety disorders 23(21.50) 161(24.73) 170(21.88) 0.463
GAD 3(2.80) 20(3.07) 21(2.70) 0.767
Panic disorder 5(4.67) 37(5.68) 30(3.87) 0.215
Agoraphobia 6(5.61) 37(5.68) 44(5.66) 0.996
Social phobia 18(16.82) 99(15.21) 112(14.41) 0.492
Current psychiatric disorders (N, %)
Any anxiety disorders 19(17.59) 89(13.63) 92(11.79) 0.083
Agoraphobia 5(4.63) 23(3.52) 24(3.08) 0.404
Social phobia 16(14.81) 69(10.57) 73(9.36) 0.108
GAD=generalized anxiety disorder; and SUA= serum uric acid.
The results are expressed as numbers and percentages except for SUA which is expressed as mean and standard deviation.
Sex-by-genotype interaction were significant for its effect on lifetime and current any anxiety disorders and social phobia (Table 4).
doi:10.1371/journal.pone.0076336.t005
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phobia across SUA levels. Solid line represents the fitted quadratic
curve of the effect of SUA on social phobia. Adjusted for age, sex,
socio-economic status, alcohol consumption, smoking, diabetes,
hypertension, GFR (calculated according to Modification in Diet
in Renal Disease equation), drugs that influence uric acid and
depression.
(TIF)
Figure S2 Distribution of serum uric acid (SUA) and
current social phobia across genotypes of SLC2A9
rs6855911 in men and women. R=women; ==men. Red
and blue barplots indicate mean SUA across the genotypes of
SLC2A9 rs6855911 in women and men respectively. Black
diamonds with bars indicate adjusted prevalence and 95% CI of
social phobia across the genotypes GG, AG and AA of the
SLC2A9 rs6855911 variant. Prevalence adjusted for age, sex,
socio-economic status, alcohol consumption, smoking, diabetes,
hypertension, GFR (calculated according to Modification in Diet
in Renal Disease equation), drugs that influence uric acid and
depression.
(TIF)
Table S1 Distribution of psychiatric disorders across
sex-specific quintiles of SUA in males. MDD=major
depressive disorder; GAD=generalized anxiety disorder; and
SUA= serum uric acid. *P-value,0.05 for quadratic trend tested
by a crude logistic model which included a quadratic term (SUA
squared) for continuous value of SUA.
(DOCX)
Table S2 Distribution of psychiatric disorders across
sex-specific quintiles of SUA in females. MDD=major
depressive disorder; GAD=generalized anxiety disorder; and
SUA= serum uric acid. *P-value,0.05 for quadratic trend tested
by a crude logistic model which included a quadratic term (SUA
squared) for continuous value of SUA.
(DOCX)
Table S3 Crude and adjusted logistic regression anal-
ysis of SUA (per 100 mmol/L) and psychiatric disorders
in males.MDD=major depressive disorder; GAD=generalized
anxiety disorder; and SUA= serum uric acid.If P value for the
quadratic term (SUA2) is significant, ORs derived from models
with quadratic term are presented.Adjusted for age, sex, socio-
economic status, alcohol consumption, smoking, diabetes, hyper-
tension, GFR (calculated according to Modification in Diet in
Renal Disease equation) and drugs that influence uric acid and
additionally for anxiety (in the association between SUA and
depression) and depression (in the association between SUA and
anxiety). *Logistic regression not possible due to zero prevalence;
NA=not available.
(DOCX)
Table S4 Crude and adjusted logistic regression anal-
ysis of SUA (per 100 mmol/L) and psychiatric disorders
in females. MDD=major depressive disorder; GAD=gener-
alized anxiety disorder; and SUA= serum uric acid. If P value for
the quadratic term (SUA2) is significant, ORs derived from models
with quadratic term are presented. Adjusted for age, sex, socio-
economic status, alcohol consumption, smoking, diabetes, hyper-
tension, GFR (calculated according to Modification in Diet in
Renal Disease equation) and drugs that influence uric acid and
additionally for anxiety (in the association between SUA and
depression) and depression (in the association between SUA and
anxiety). *Logistic regression not possible due to zero prevalence;
NA=not available.
(DOCX)
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